The global vaccine market was reported to be $36 billion in 2018 and expected to rise to $50 billion by 2023. The flu vaccine market alone was reported to be $3.3 billion in 2018 rising to $4.6 Billion in 2023. Approximately 35% of the vaccine market is in the US. Currently there is a large requirement for new, safer and better vaccines, see the WHO report here: https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf. On page 13 of this report COPD is described as needing 6% of the total healthcare spending, amounting to $38.6 billion annually. Vaccines are the most effective way of preventing exacerbation and death in COPD.
An example of the requirement for better vaccines is TB. Although the current TB market is relatively small it’s estimated that it could grow to several billion, see here: http://www.aeras.org/pdf/TB_RD_Business_Case_Draft_3.pdf
Other markets for the technology include respiratory syncytial virus and rhinovirus. The technology is particularly suited for airborne infections and therefore may be applicable to a number of pandemic threats including pandemic flu, MERS, SARS, and disease X.
The veterinary vaccine market is reported to be $7.2 billion in 2018 rising to $9.1 billion in 2022.
Alliances & Collaborations
Strategic alliances have been established with the key aerosolizer developer and manufacturer, with leading vaccine academics and universities, with one of the leading global infection challenge CROs and with government departments in particular PHE, Porton Down.
As mentioned above key collaborations are being established with an aerosolizer developer and manufacturer, CROs, leading research centres, and vaccine companies.